Menopause study
Seven outcomes.
Measurable results.
“Efficacy and Safety of Shatavari (Asparagus racemosus) Root Extract in the Management of Menopausal Symptoms: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.”Published · Natural Resources for Human Health, 2026
Study design.
- Design
- Multicentre, randomised, double-blind, placebo-controlled trial
- Participants
- 70 healthy peri- and postmenopausal women aged 45 to 55, with moderate symptoms: a Menopause Rating Scale score of 9 to 16 and more than ten hot flashes a week
- Intervention
- Aspargize™ at 400 mg a day, or placebo, for 56 days; assessed at days 14, 28, 42 and 56
- Measured
- Primary: the hot-flush score and the climacteric symptom score (MRS). Secondary: perceived stress, menopause-specific quality of life, mood, sleep quality and serum estradiol. Exploratory: salivary cortisol, FSH, LH and testosterone
Key outcomes.
The results.
Significant from day 14. **p ≤ 0.01, ****p ≤ 0.0001 vs placebo.
Significant from day 14. *p ≤ 0.05, ****p ≤ 0.0001 vs placebo.
Also measured.
Serum estradiol improved, and luteinising hormone and follicle-stimulating hormone decreased (bi-directional hormonal support), within the healthy reference range for menopausal women. Salivary cortisol decreased significantly by day 42.
No clinically meaningful safety concerns: safe for use.
The publication.
“Efficacy and Safety of Shatavari (Asparagus racemosus) Root Extract in the Management of Menopausal Symptoms: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.” Natural Resources for Human Health, 2026.
Full text available on request.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Next step
Working with ?
Tell us the format and the market, and we will send a sample with its specification.